News & Events

The Translational Readout #2 - Tumor Heterogeneity: Why Treatment Responses Differ

8 September 2026

Tumors of the same diagnosis can differ substantially in their biology. The same treatment may therefore work differently between patients โ€“ and even across cells within a single tumor.

Read more

๐ŸŽ‰ ๐Ÿญ๐Ÿฌ ๐—ฌ๐—ฒ๐—ฎ๐—ฟ๐˜€ ๐—ผ๐—ณ ๐—ฉ๐—ถ๐˜๐—ฟ๐—ผ๐—ฆ๐—ฐ๐—ฎ๐—ป!

3 September 2026

Today we celebrate an exciting milestone: 10 years of VitroScan! Over the past decade, we have grown, learned, innovated, and taken important steps towards our mission of supporting better informed treatment decisions for cancer patients through ex vivo micro-tumor testing.

Read more

VitroScan featured in news items on Dutch national radio and television!

3 September 2026

The items focused on the need for a national investment bank, as outlined in the Rapport Wennink, and on a broader question facing the Netherlands: how can we strengthen our long-term economic growth through innovation?

Read more

The Translational Readout #1 - Functional Precision Oncology: Beyond Molecular Profiling

4 August 2026

Molecular profiling identifies patients that may benefit from specific therapies. Functional profiling provides direct evidence of how patient-derived tumor tissue responds to therapies ex vivo. Together, they offer a more comprehensive understanding of treatment response.

Read more

VitroScan and Radboudumc join forces to advance novel cell therapy for ovarian cancer patients

26 May 2026

We are proud to announce the launch of the EXACCT project, a new collaboration between VitroScan and Radboudumc focused on advancing innovative CAR-NK cell therapies for ovarian cancer patients.

Read more

VitroScan featured in the latest edition of BiotechNews

21 May 2026

Excited to see VitroScan featured in the latest edition of BiotechNews! The article highlights our mission to advance precision oncology through predictive ex vivo micro-tumor testing, helping physicians and their patients make better informed treatment decisions.

Read more

VitroScan presented twice at the AACR2026 annual meeting

22 April 2026

Proud to see our very own Felix Behr, PhD presenting twice at the recent #AACR2026 annual meeting with both an oral and a poster presentation showcasing how our ex vivo micro-tumor platform can help characterize and predict patient-specific responses to ADCs and immunotherapies.

Read more

VitroScan Shares ChemoPredict Journey at Biotech Booster Annual Event

11 March 2026

CEO Willemijn Vader and PSC Chair Joris Schuurmans highlighted lessons learned in the ChemoPredict Biotech Booster project from scientific innovation towards a market-ready solution.

Read more

A Major Milestone for VitroScan: ISO 15189 Compliance! ๐ŸŽ‰

10 March 2026

As of Marchโ€ฏ2026, VitroScan is operating under an ISO 15189 compliant quality management system. This internationally recognized quality standard sets the benchmark for excellence in medical laboratories, ensuring that every clinical sample analysis meets the highest levels of quality, reliability, and regulatory compliance.

Read more

Biotech Booster Annual Event 2026 on March 10: Willemijn Vader and Joris Schuurmans will present ChemoPredict project journey

5 February 2026

Join Willemijn Vader, CEO at VitroScan, and Joris Schuurmans, Chair of the ChemoPredict project steering committee, at the Biotech Booster Annual Event on March 10.

Read more

VitroScan awarded Kansen voor West grant to advance ex vivo tumor testing for next-generation immunotherapies

29 October 2025

VitroScan awarded 'Kansen voor West'-grant to advance ex vivo tumor testing for next-generation immunotherapies

Read more

VitroScan's micro-tumor test accurately predicts chemotherapy response for ovarian cancer patients

9 September 2025

VitroScan is proud to announce the publication of a study showing its 3D ex vivo micro-tumor testing platform can accurately predict whether an ovarian cancer patient will respond to chemotherapy.

Read more